Suppr超能文献

设计、合成及生物评价一系列新型噻唑基-吡唑啉衍生物作为双重 EGFR 和 HER2 抑制剂。

Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.

机构信息

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, 26470, Turkey.

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, 26470, Turkey.

出版信息

Eur J Med Chem. 2019 Nov 15;182:111648. doi: 10.1016/j.ejmech.2019.111648. Epub 2019 Aug 28.

Abstract

Epidermal growth factor receptor (EGFR, also known as HER1) and HER2, prominent members of receptor tyrosine kinase (RTK) superfamily, have been reported as diagnostic or prognostic markers in tumor progression. Based on the importance of molecular hybridization of pyrazoline and thiazole scaffolds in the discovery of potent anticancer agents, new thiazolyl-pyrazoline derivatives (3a-v) were synthesized and screened for their cytotoxic effects on A549 human lung adenocarcinoma, MCF-7 human breast adenocarcinoma and A375 human melanoma cell lines. 1-(4-(4-Fluorophenyl)thiazol-2-yl)-3-(4-morpholinophenyl)-5-(4-chlorophenyl)-2-pyrazoline (3c),1-(4-(4-cyanophenyl)thiazol-2-yl)-3-(4-morpholinophenyl)-5-(4-chlorophenyl)-2-pyrazoline (3f) and 1-(4-(4-cyanophenyl)thiazol-2-yl)-3-(4-piperidinophenyl)-5-(4-chlorophenyl)-2-pyrazoline (3q) were found as the most potent anticancer agents against A549 and MCF-7 cell lines compared to erlotinib. Compound 3q also showed moderate cytotoxic activity against A375 cell line. Moreover, these compounds exert a cancer cell-selective action against Jurkat cell line posing no toxicity on peripheral blood mononuclear cells (PBMCs). In order to enlighten the mechanism of action underlying anticancer activity, compounds 3c, 3f and 3q were investigated for their apoptotic effects on A549 and MCF-7 cell lines and inhibitory potencies against eight different RTKs including EGFR and HER2 compared to erlotinib. The results indicated that compounds 3f and 3q induced apoptosis in both cell lines and showed significant EGFR inhibitory activity with IC values of 4.34 ± 0.66 μM and 4.71 ± 0.84 μM, respectively when compared with erlotinib (IC = 0.05 ± 0.01 μM). Besides, compound 3f also inhibited HER2 notably with an IC value of 2.28 ± 0.53 μM making it a dual EGFR and HER2 inhibitor. Molecular docking studies, which were conducted to support the in vitro assays, pointed out that compound 3f showed high affinity into the ATP binding sites of EGFR and HER2.

摘要

表皮生长因子受体(EGFR,也称为 HER1)和 HER2 是受体酪氨酸激酶(RTK)超家族的重要成员,已被报道为肿瘤进展的诊断或预后标志物。基于吡唑啉和噻唑骨架在发现有效抗癌药物中的分子杂交的重要性,合成了新的噻唑基吡唑啉衍生物(3a-v),并对其在 A549 人肺腺癌细胞、MCF-7 人乳腺癌细胞和 A375 人黑色素瘤细胞系中的细胞毒性进行了筛选。1-(4-(4-氟苯基)噻唑-2-基)-3-(4-吗啉基苯基)-5-(4-氯苯基)-2-吡唑啉(3c)、1-(4-(4-氰基苯基)噻唑-2-基)-3-(4-吗啉基苯基)-5-(4-氯苯基)-2-吡唑啉(3f)和 1-(4-(4-氰基苯基)噻唑-2-基)-3-(4-哌啶基苯基)-5-(4-氯苯基)-2-吡唑啉(3q)被发现是针对 A549 和 MCF-7 细胞系的最有效的抗癌药物,比厄洛替尼更有效。与厄洛替尼相比,化合物 3q 对 A375 细胞系也表现出中等的细胞毒性活性。此外,这些化合物对 Jurkat 细胞系具有癌细胞选择性作用,对外周血单核细胞(PBMCs)没有毒性。为了阐明抗癌活性的作用机制,研究了化合物 3c、3f 和 3q 对 A549 和 MCF-7 细胞系的凋亡作用以及对包括 EGFR 和 HER2 在内的 8 种不同 RTKs 的抑制作用,与厄洛替尼相比。结果表明,化合物 3f 和 3q 在两种细胞系中均诱导凋亡,并表现出显著的 EGFR 抑制活性,IC 值分别为 4.34±0.66μM 和 4.71±0.84μM,而厄洛替尼的 IC 值为 0.05±0.01μM。此外,化合物 3f 还显著抑制 HER2,IC 值为 2.28±0.53μM,使其成为 EGFR 和 HER2 的双重抑制剂。进行了分子对接研究,以支持体外测定,指出化合物 3f 显示出与 EGFR 和 HER2 的 ATP 结合位点的高亲和力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验